CN115957249A - Application of tripterygium wilfordii bidirectional solid fermentation product in preparation of medicine for treating kidney disease - Google Patents
Application of tripterygium wilfordii bidirectional solid fermentation product in preparation of medicine for treating kidney disease Download PDFInfo
- Publication number
- CN115957249A CN115957249A CN202211722631.5A CN202211722631A CN115957249A CN 115957249 A CN115957249 A CN 115957249A CN 202211722631 A CN202211722631 A CN 202211722631A CN 115957249 A CN115957249 A CN 115957249A
- Authority
- CN
- China
- Prior art keywords
- tripterygium wilfordii
- solid fermentation
- bidirectional solid
- fermentation product
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of a tripterygium wilfordii bidirectional solid fermentation product in preparation of a medicine for treating nephropathy, belongs to the technical field of traditional Chinese medicine preparations, and particularly discloses an application of the tripterygium wilfordii bidirectional solid fermentation product in preparation of a medicine for treating nephropathy, which can achieve the technical effects of low toxic and side effects and good treatment effect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparations, in particular to application of a tripterygium wilfordii bidirectional solid fermentation product in preparation of a medicine for treating kidney diseases.
Background
Chronic Kidney Disease (CKD) is a Chronic nephrotic syndrome with abnormal structure and function of Chronic kidney caused by primary or secondary kidney disease caused by multiple factors, clinically including Chronic glomerulonephritis, nephrotic syndrome, membranous nephropathy, diabetic nephropathy, hypertensive nephropathy and various secondary nephropathy, etc., which become global public health problems, the prevalence rate of Chronic kidney disease in china is as high as 10.8%, and the prevalence rate and the fatality rate are continuously increased, and as renal function is progressively reduced, CKD patients are often accompanied with various complications, such as anemia, mineral and bone metabolic abnormality, cardiovascular disease and infection, etc. Currently, there is no specific method for preventing and treating chronic kidney disease, and modern medicine mainly controls primary disease and treats disease to delay the progression of CKD, but most patients eventually progress to chronic renal failure, resulting in death due to various complications.
The chronic renal failure belongs to the categories of edema, urine retention, obstruction and the like in traditional Chinese medicine, the pathogenesis is the deficiency of the principal and the secondary excess, the treatment is based on strengthening the body resistance to eliminate pathogenic factors and the treatment is based on both the principal and the secondary aspects, and the traditional Chinese medicine has unique features in the aspects of preventing and treating diseases. Although dialysis or kidney transplantation is a treatment for the end-stage survival of patients with chronic renal failure, it is an ideal method to adopt effective medication measures to effectively prevent or delay the progress of chronic renal failure based on the primary onset of the treatment in the early and middle stages of chronic renal failure.
Researches show that the traditional Chinese medicine can effectively prevent or delay the progressive deterioration of renal function and delay the development of chronic renal failure for patients with early and middle stage chronic renal failure, and the researches show that the tripterygium wilfordii has good clinical curative effects on immune diseases, kidney diseases, skin diseases and the like, however, the curative dose of the tripterygium wilfordii is very close to the toxic dose, the toxic and side effect incidence rate is 58.1 percent, and the clinical application of the tripterygium wilfordii is greatly limited, for example, chinese patent invention with publication No. CN104398564A discloses a traditional Chinese medicine composition containing tripterygium wilfordii for treating gout, the pharmacological action of the tripterygium wilfordii is effectively applied through a traditional Chinese medicine efficacy screening platform, but how to reduce the toxic and side effects of the tripterygium wilfordii when the tripterygium wilfordii is applied is not disclosed. In order to better exert the clinical application value of tripterygium wilfordii and reduce the toxic and side effects of the tripterygium wilfordii, attenuated storage/synergistic processing of the tripterygium wilfordii is always concerned. At present, various processing methods such as cleaning, steaming, stir-frying, wine processing, vinegar processing, sheep blood processing, liquorice processing, white paeony root processing, desmodium processing, radish seed juice processing and the like are available. Although various processing methods exist at present, researches on bidirectional solid fermentation are few, and the application of the bidirectional solid fermentation product of the thunder god vine in chronic kidney diseases is not found at present.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide the application of the traditional Chinese medicine composition with low toxic and side effects and good treatment effect in treating chronic kidney diseases.
In order to solve the technical problems, the invention adopts the technical scheme that: application of a bidirectional solid fermentation product of radix Tripterygii Wilfordii in preparing medicine for treating nephropathy is provided.
The preparation method of the tripterygium wilfordii bidirectional solid fermentation comprises the following steps:
s1, inoculating fermentation strains into a fermentation substrate to perform bidirectional solid fermentation to obtain a medicinal substrate;
s2, drying the medicinal substrate and then crushing the medicinal substrate;
and S3, wrapping the crushed medicinal substrates by using a filter screen, and decocting in water.
The invention has the beneficial effects that: in the process of bidirectional solid fermentation, the tripterygium wilfordii not only can be used as a nutrient substrate to provide nutrition for fungi, but also can change the components or the drug effect of the tripterygium wilfordii by virtue of the enzymolysis of the fungi, further reduce the toxic and side effects of the tripterygium wilfordii, and better play the clinical application value of the tripterygium wilfordii in treating chronic kidney diseases.
Drawings
FIG. 1 is a total ion flow diagram of the tripterygium wilfordii bidirectional solid fermentation product of the present invention;
FIG. 2 is a graph showing the blood creatinine and urea nitrogen levels in various groups of rats according to example 3 of the present invention;
FIG. 3 shows pathological changes of kidney in each group of rats in example 3 of the present invention.
Detailed Description
In order to explain technical contents, achieved objects, and effects of the present invention in detail, the following description is made with reference to the accompanying drawings in combination with the embodiments.
The most key concept of the invention is as follows: the application of the tripterygium wilfordii bidirectional solid fermentation product in preparing the medicine for treating the chronic kidney disease caused by adenine achieves the technical effects of low toxic and side effects and good treatment effect.
The invention relates to application of a tripterygium wilfordii bidirectional solid fermentation product in preparation of a medicament for treating kidney diseases.
From the above description, the beneficial effects of the present invention are: the product of the bidirectional solid fermentation of the tripterygium wilfordii can reduce the toxic and side effect of the tripterygium wilfordii and is used for preparing the medicine for treating the chronic kidney disease caused by adenine at the same time.
Further, the preparation method of the tripterygium wilfordii bidirectional solid fermentation comprises the following steps:
s1, inoculating a fermentation strain into a fermentation substrate to perform bidirectional solid fermentation to obtain a drug property substrate;
s2, drying the medicinal substrate and then crushing the medicinal substrate;
and S3, wrapping the crushed medicinal substrates by using a filter screen, and decocting in water.
From the above description, thunder god vine has excellent clinical curative effect on immune diseases, kidney diseases, skin diseases and the like, however, the therapeutic dose of the thunder god vine is very close to the toxic dose, and in a plurality of processing methods, bidirectional solid fermentation has more prospects, and in the bidirectional solid fermentation process, the thunder god vine not only can be used as a nutrient substrate to provide nutrition for fungi, but also can change the components or the drug effect of the thunder god vine by virtue of the enzymolysis of the fungi, thereby providing possibility for realizing the deep development and application of the thunder god vine.
Further, the fermentation strain is a ganoderma lucidum strain.
From the above description, the components or drug effects of Tripterygium wilfordii are changed by the enzymolysis of the Ganoderma lucidum. Preferably, the Ganoderma strain is Ganoderma sinense (Ganoderma lucidum)
Further, the fermentation substrate is composed of tripterygium wilfordii and astragalus according to a weight ratio of 1.
From the above description, tripterygium wilfordii and Astragalus membranaceus are used as nutrient substrates to provide nutrients for fungi.
Further, the fermentation time of the bidirectional solid fermentation is 30d.
As can be seen from the above description, the fermentation is made more complete.
Furthermore, the filter screen is a gauze, and the number of layers of the gauze is 8.
From the above description, the effective components of the medicated matrix are fully dissolved in water by using multiple layers of gauze.
Further, the decoction time is 45min.
As can be seen from the above description, the decoction time is limited so that the active ingredients of the drug substance matrix are fully decocted out.
Further, the tripterygium wilfordii comprises the following components in parts by weight: astragalus root: water =1:1:10 to 15.
From the above description, it can be seen that the composition is formulated in a certain proportion to exert better therapeutic effect.
Example 1 of the present invention is:
the specific process of the tripterygium wilfordii bidirectional solid fermentation is as follows:
accurately weighing 100g of tripterygium wilfordii and 100g of astragalus mongholicus, adding ganoderma lucidum strains, fermenting for 30d, drying a medicinal substrate, crushing, wrapping decoction with eight layers of gauze, adding 1L of water, and decocting for 45min to obtain a tripterygium wilfordii bidirectional solid fermentation product, wherein the tripterygium wilfordii bidirectional solid fermentation product is used as a medicine for treating chronic kidney diseases.
Example 2 of the present invention is:
the tripterygium wilfordii bidirectional solid fermentation product in the example 1 is used for identifying chemical components and screening active components.
Taking the tripterygium wilfordii bidirectional solid fermentation product of example 1, centrifuging for 15min (centrifugation condition: 4 ℃,12000 rpm), taking 300 μ L of supernatant into an EP tube, adding 1000 μ L of extracting solution (methanol: water =4, internal standard concentration is 10 μ g/mL); vortex for 30s, and then ultrasonically treating for 5min in an ice water bath; after standing at-40 ℃ for 1 hour, the sample was centrifuged for 15min (centrifugation conditions: 4 ℃ C., 12000 rpm), and the supernatant was filtered through a 0.22 μm microfiltration membrane.
The analysis was performed using mobile phase parameters in Table 1 under the control of Vanqish (Thermo Fisher Scientific) ultra performance liquid phase. The column used was an UPLC BEH C18 column (1.7 μm 2.1X 100mm) from Waters, with a sample volume of 5 μ L, where time is in min and flow rate is in μ L/min, and 0.1% formic acid was added to both phase A and phase B.
Primary and secondary mass spectral data acquisition was performed using the Orbitrap explores 120 mass spectrometer. The detailed parameters are as follows: shear gas flow rate:35Arb, aux gas flow rate.
Obtaining a total ion flow diagram (TIC) of the tripterygium wilfordii bidirectional solid fermentation product, which is shown in fig. 1, wherein a in fig. 1 is the total ion flow diagram of the tripterygium wilfordii bidirectional solid fermentation product in a positive ion mode, and B in fig. 1 is the total ion flow diagram of the tripterygium wilfordii bidirectional solid fermentation product in a negative ion mode.
TABLE 1
Referring to fig. 1 to 3, an embodiment 3 of the present invention is:
the effect of the tripterygium wilfordii bidirectional solid fermentation product in example 1 on adenine-induced chronic renal failure animal model:
18 male SD rats (180-220 g) were purchased from the medical laboratory animals center of Guangdong province (Foshan, china, licensed by SCXK, 2013-0002[ YuE ]). CKD model group CKD-induced animal models were induced by feeding for 3 weeks with 0.75% adenine-containing feed, and normal group was given normal feeding, and 18 male SD rats were randomly divided into 3 groups: normal group (Control, n = 6), model group (CKD, n = 6), thunder god vine fermentation product treatment group (CKD + lgt. Hq, n = 6). The CKD + LGT.HQ group was intragastrically administered with the fermented product of Tripterygium wilfordii (g/kg/day) for 4 weeks, and the remaining groups were intragastrically administered with an equal volume of ultrapure water. After the dosing was completed, the rats were sacrificed and serum and kidney tissue were retained for follow-up studies. The results showed significant increases in blood creatinine and urea nitrogen levels in the CKD model group compared to the normal group (see fig. 2), wherein the left panel in fig. 2 is the blood creatinine and urea nitrogen levels in each group of rats where p <0.0001, and the right panel in fig. 2 is the blood creatinine and urea nitrogen levels in each group of rats where p < 0.0005. Compared with the normal group, the CKD model group has the advantages that the number of glomerular capillaries is reduced, part of capillary loops are unevenly distributed, and the lumen is closed. The residual glomerular capsule expands, the capsule wall of Bowman's capsule thickens, the basement membrane thickens and the mesangial proliferates. The renal tubular epithelial cells are vacuolized and degenerated, necrosis occurs, partial lumen compensatory expansion occurs, a large amount of inflammatory cells infiltrate into renal interstitium, interstitial fibrosis is obvious, and pathological changes of rat kidney tissues are obvious (see figure 3), wherein figure 3 shows the pathological changes of rat kidneys of a normal group, a model group and a treatment group. The fermentation product of radix Tripterygii Wilfordii can significantly reduce blood creatinine and urea nitrogen levels (see figure 2), significantly improve pathological damage of kidney tissue (see figure 3), and delay the progression of chronic renal failure.
In conclusion, the application of the tripterygium wilfordii bidirectional solid fermentation product in preparing the medicament for treating the kidney disease can reduce the toxic and side effect of the tripterygium wilfordii and simultaneously be used for preparing the medicament for treating the chronic kidney disease caused by adenine; in the bidirectional solid fermentation process, the tripterygium wilfordii not only can be used as a nutrient substrate to provide nutrition for fungi, but also can change the components or the drug effect of the tripterygium wilfordii by virtue of the enzymolysis of the fungi, thereby providing possibility for realizing the deep development and application of the tripterygium wilfordii.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all equivalent changes made by using the contents of the present specification and the drawings, or applied directly or indirectly to the related technical fields, are included in the scope of the present invention.
Claims (8)
1. Application of a bidirectional solid fermentation product of radix Tripterygii Wilfordii in preparing medicine for treating nephropathy is provided.
2. The application of the tripterygium wilfordii bidirectional solid fermentation product in the preparation of the medicine for treating the kidney disease according to claim 1, wherein the preparation method of the tripterygium wilfordii bidirectional solid fermentation comprises the following steps:
s1, inoculating a fermentation strain into a fermentation substrate to perform bidirectional solid fermentation to obtain a drug property substrate;
s2, drying the medicinal substrate and then crushing the medicinal substrate;
and S3, wrapping the crushed medicinal substrates by using a filter screen, and decocting in water.
3. The application of the tripterygium wilfordii bidirectional solid fermentation product in the preparation of the medicine for treating the kidney disease as claimed in claim 2, wherein the fermentation strain is a ganoderma lucidum strain.
4. The application of the tripterygium wilfordii bidirectional solid fermentation product in the preparation of the medicine for treating the kidney disease according to claim 2, wherein the fermentation substrate is tripterygium wilfordii and astragalus membranaceus in a weight ratio of 1.
5. The application of the tripterygium wilfordii bidirectional solid fermentation product in the preparation of drugs for treating kidney diseases according to claim 2, wherein the fermentation time of the bidirectional solid fermentation is 30 days.
6. The application of the tripterygium wilfordii bidirectional solid fermentation product in preparing a medicine for treating kidney diseases according to claim 2, wherein the filter screen is gauze, and the number of the gauze layers is 8.
7. The use of the bi-directional solid fermentation product of Tripterygium wilfordii hook F according to claim 2 for the preparation of a medicament for treating kidney disease, wherein the decoction period is 45min.
8. The application of the tripterygium wilfordii bidirectional solid fermentation product in the preparation of drugs for treating kidney diseases according to claim 2, wherein the tripterygium wilfordii bidirectional solid fermentation product comprises the following components in parts by weight: astragalus root: water =1:1:10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211722631.5A CN115957249A (en) | 2022-12-30 | 2022-12-30 | Application of tripterygium wilfordii bidirectional solid fermentation product in preparation of medicine for treating kidney disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211722631.5A CN115957249A (en) | 2022-12-30 | 2022-12-30 | Application of tripterygium wilfordii bidirectional solid fermentation product in preparation of medicine for treating kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115957249A true CN115957249A (en) | 2023-04-14 |
Family
ID=87359815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211722631.5A Pending CN115957249A (en) | 2022-12-30 | 2022-12-30 | Application of tripterygium wilfordii bidirectional solid fermentation product in preparation of medicine for treating kidney disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115957249A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911262A (en) * | 2005-08-08 | 2007-02-14 | 庄毅 | Application of medical fungi bidirection solid fermentation engineering technology in processing thunder godvine to detoxify and keep effect |
| CN103597071A (en) * | 2011-01-07 | 2014-02-19 | 埃尔舍利克斯治疗公司 | Chemosensory receptor ligand-based therapies |
-
2022
- 2022-12-30 CN CN202211722631.5A patent/CN115957249A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911262A (en) * | 2005-08-08 | 2007-02-14 | 庄毅 | Application of medical fungi bidirection solid fermentation engineering technology in processing thunder godvine to detoxify and keep effect |
| CN103597071A (en) * | 2011-01-07 | 2014-02-19 | 埃尔舍利克斯治疗公司 | Chemosensory receptor ligand-based therapies |
Non-Patent Citations (3)
| Title |
|---|
| 周雪娥;谢卫华;罗闳丹;苏明声;谢小梅;庄毅;: "灵雷菌质对阿霉素诱导大鼠肾病模型的作用", 中草药, no. 05, pages 771 - 774 * |
| 谢小梅;贺婧;罗闳丹;苏明声;张普照;庄毅;: "灵芝双向发酵雷公藤的解毒持效作用", 中草药, vol. 40, no. 12, pages 1925 - 1929 * |
| 陶玲;肖芳;朱卫丰;陈丽华;管咏梅;金晨;吴璐;: "雷公藤减毒研究进展", 中国实验方剂学杂志, vol. 23, no. 05, pages 229 - 234 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103750107B (en) | Health-care product with blood glucose reducing function | |
| CN109718257A (en) | A kind of Phellinus fruiting body extract and its application in preparation treatment chronic renal failure drug | |
| CN113543795A (en) | Sunflower head and coix seed compound composition and application thereof in preparation of medicine for treating liver injury | |
| CN102488806A (en) | Renal failure treating Chinese medicinal preparation and preparation method thereof | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN104983987B (en) | Traditional Chinese medicine colon dialysis liquid for treating chronic renal failure | |
| CN103316101B (en) | Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof | |
| CN115957249A (en) | Application of tripterygium wilfordii bidirectional solid fermentation product in preparation of medicine for treating kidney disease | |
| CN102078397A (en) | Traditional Chinese medicine compound and preparation method thereof | |
| CN102018903B (en) | Pure traditional Chinese medicine preparation for treating glomerular diseases and preparation method thereof | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN107088206A (en) | A kind of preparation method and applications of mulberry bark extract | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN1557378A (en) | Medicine for treating diabetes | |
| CN108653559A (en) | A kind of hypoglycemic composition and its application | |
| CN1557416A (en) | Medicine preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1733055A (en) | Fenugreek seed extract and its preparing process and application | |
| CN104257755A (en) | Composition with effect of treating diabetes as well as preparation method and application of composition | |
| CN105535070B (en) | The pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN100484543C (en) | Medicament composition for treating hepatitis, prepartion method and use | |
| CN103446494B (en) | Chinese patent medicine for treating Type II diabetic nephropathy and preparation method thereof | |
| CN102488805A (en) | Method for preparing Shenshuaining preparations with polymeric flocculation and precipitation technology | |
| CN111110714B (en) | Chinese medicinal preparation for treating angina pectoris and atherosclerosis diseases and preparation method thereof | |
| CN101966251B (en) | Medicinal composition for preventing and treating bronchial asthma and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |